We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01233570
Recruitment Status : Completed
First Posted : November 3, 2010
Last Update Posted : November 3, 2010
Information provided by:
University of Aberdeen

Brief Summary:
An assessment of the efficacy of topical tacrolimus in the treatment of cutaneous crohns disease

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Tacrolimus Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Tacrolimus

Arm Intervention/treatment
Experimental: Topical tacrolimus
Once daily topical application
Drug: Tacrolimus
Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
Other Names:
  • Protopic 0.1%
  • FK506

Primary Outcome Measures :
  1. Assessment of standardised digital photography by three independent assessors following the Physicians' Global Severity Scale before and after treatment [ Time Frame: At 12 weeks of treatment, optionally extended to 52 weeks ]

Secondary Outcome Measures :
  1. Global Self Assessment [ Time Frame: 12 weeks, optionally extended to 52 weeks ]
  2. Perineal Disease Activity Index [ Time Frame: 12 weeks, optionally extended to 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • willingness and capability to follow the study procedure
  • confirmed diagnosis of Crohn's Disease of at least 3 months duration confirmed by radiography, endoscopy or pathological examination
  • required to have a skin manifestation of Crohn's disease
  • required to give written informed consent
  • both male and female subjects with reproductive potential required to be on an acceptable form of birth control for the duration of the study
  • long-standing, concomitant immunosuppressive therapy was allowed if the dose was stable and not controlling the skin problem

Exclusion Criteria:

  • known sensitivity to tacrolimus
  • change in aminosalicylate dosage in the four weeks prior to screening
  • on oral steroids at over 40mg per day
  • been commenced on methotrexate, azathoprine or ciclosporin within the last two months
  • commenced on a a TNF-alpha monoclonal antibody within the three months prior to screening
  • patients having had a stoma fashioned less than three months before enrolment
  • patients with an immunocompromising disease
  • patients with a diagnosis of malignancy within the last five years
  • patients with any other condition, past or present treatment thought by the investigator to render the subject ineligible for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01233570

Layout table for location information
United Kingdom
University of Aberdeen, Aberdeen Royal Infirmary
Aberdeen, Grampian, United Kingdom, AB25 2ZN
Sponsors and Collaborators
University of Aberdeen
Layout table for investigator information
Principal Investigator: Anthony D Ormerod, MBChB University of Aberdeen
Layout table for additonal information
Responsible Party: Dr AD Ormerod, University of Aberdeen
ClinicalTrials.gov Identifier: NCT01233570    
Other Study ID Numbers: 33000332
First Posted: November 3, 2010    Key Record Dates
Last Update Posted: November 3, 2010
Last Verified: November 2010
Keywords provided by University of Aberdeen:
Cutaneous Crohns Disease
Topical Tacrolimus
Metastatic Crohns Disease
Pyoderma Gangrenosum
Granulomatous chelitis
Oral crohns disease
Perianal crohns disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action